Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) CEO Talat Imran bought 10,296 shares of the stock in a transaction on Monday, December 9th. The shares were acquired at an average cost of $1.94 per share, for a total transaction of $19,974.24. Following the purchase, the chief executive officer now owns 494,751 shares in the company, valued at approximately $959,816.94. This represents a 2.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Rani Therapeutics Stock Down 1.6 %
Shares of Rani Therapeutics stock opened at $1.90 on Wednesday. The firm has a market cap of $108.85 million, a price-to-earnings ratio of -1.79 and a beta of 0.05. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. Rani Therapeutics Holdings, Inc. has a 52-week low of $1.85 and a 52-week high of $8.75. The stock has a 50-day simple moving average of $2.27 and a 200-day simple moving average of $2.91.
Institutional Investors Weigh In On Rani Therapeutics
Several institutional investors have recently made changes to their positions in RANI. Vanguard Group Inc. lifted its holdings in Rani Therapeutics by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 685,303 shares of the company's stock worth $2,131,000 after purchasing an additional 16,956 shares during the last quarter. Stifel Financial Corp lifted its holdings in Rani Therapeutics by 100.4% in the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company's stock worth $583,000 after purchasing an additional 135,148 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Rani Therapeutics by 14.3% in the 3rd quarter. Geode Capital Management LLC now owns 172,261 shares of the company's stock worth $372,000 after purchasing an additional 21,527 shares during the last quarter. King Luther Capital Management Corp lifted its holdings in Rani Therapeutics by 44.5% in the 3rd quarter. King Luther Capital Management Corp now owns 81,129 shares of the company's stock worth $175,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Rani Therapeutics in the 2nd quarter worth approximately $81,000. 30.19% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Tuesday, November 19th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $11.71.
View Our Latest Stock Report on RANI
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
